Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

被引：0
|
作者：
Hannah A. Blair
机构：
[1] Springer,
来源：
Drugs | 2018年 / 78卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original article has been corrected.
引用
收藏
页码：1911 / 1911
相关论文
共 50 条
  • [41] Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia
    Pea, F
    Russo, D
    Michieli, M
    Damiani, D
    Fanin, R
    Michelutti, A
    Michelutti, T
    Piccolrovazzi, S
    Baccarani, M
    Furlanut, M
    CLINICAL PHARMACOKINETICS, 2003, 42 (09) : 851 - 862
  • [42] Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review
    Kline, JP
    Larson, RA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2711 - 2718
  • [43] Validation of AML-Score in older adults receiving daunorubicin/cytarabine liposome intensive induction chemotherapy for treatment of secondary acute myeloid leukemia.
    Schmucker, Abigail
    Leiby, Benjamin
    Wilde, Lindsay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia
    Masaoka, T
    Ogawa, M
    Yamada, K
    Kimura, K
    Ohashi, Y
    SEMINARS IN HEMATOLOGY, 1996, 33 (04) : 12 - 17
  • [45] Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
    Brandt, K.
    Schaekel, K.
    Stoelzel, F.
    Janschek, J.
    Ehninger, G.
    Schaich, M.
    CASE REPORTS IN ONCOLOGY, 2010, 3 (03): : 349 - 353
  • [46] Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia
    Krogh-Madsen, Mikkel
    Honore, Steen Hansen
    Jensen, Morten Krogh
    Nielsen, Ove Juul
    Jensen, Hannah Sondergaard
    Honore, Per Hartvig
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2013, 20 (03): : 185 - 188
  • [47] Petechiae, suffusions and cytarabine-induced erythema in the treatment of acute myeloid leukaemia
    Taverna, C
    Jacky, E
    Sauter, C
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 128 (27-28) : 1117 - 1117
  • [48] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
  • [49] Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
    Bewersdorf, Jan Philipp
    Patel, Kishan K.
    Goshua, George
    Shallis, Rory M.
    Podoltsev, Nikolai A.
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2022, 139 (11) : 1766 - 1770
  • [50] Use of daunorubicin and cytarabine in adults with acute myeloid leukemia and associated risk factors for inpatient mortality: National inpatient sample review
    Pagidipally, Alekhya
    Sharma, Shivani
    Chennapragada, Suma Sri
    Dandwani, Mehndi
    Ramphul, Kamleshun
    Verma, Renuka
    Sanikommu, Sailaja
    Arti, Fnu
    Kumar, Vijay
    Sombans, Shaheen
    Ramphul, Yogeshwaree
    Mejias, Stephanie G.
    Dhillon, Balkiranjit Kaur
    Lohana, Petras
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345